ALPMY Financials: Astellas Pharma Inc. AI Analysis



Financials

ALPMY Financial

Astellas Pharma Inc.

$13.26

1.6%

$0.2

As of today:Jul 14, 14:15:21 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$13.05

Open

$13.23

Day's Range

$13.22 - $13.33

52 week range

$9.46 - $17.35

Volume

18.5K

Avg.Volume

188.9K

Dividend yield

EPS (TTM)

1.00

Market Cap

$23.7B

What is Astellas Pharma, Inc.?

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To. The firm mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.

Features

Markets

News

Breakdown	TTM	03/31/2026	12/31/2025	09/30/2025	06/30/2025	03/31/2025
Revenue	2,139,245	537,925	571,206	524,320	505,794	459,294
Revenue Growth (YoY)	12%	17%	10%	13%	7%	11%
Cost of Revenue	408,426	93,667	114,400	105,530	94,829	76,858
Gross Profit	1,730,819	444,258	456,806	418,790	410,965	382,436
Selling, General & Admin	860,312	234,699	221,779	206,837	196,997	211,316
Research & Development	314,827	95,943	75,595	71,591	71,698	76,229
Operating Expenses	1,350,760	395,690	322,264	314,382	318,424	319,334
Other Non Operating Income (Expenses)	--	--	--	--	--	1
Pretax Income	376,587	48,024	133,957	104,189	90,417	60,554
Income Tax Expense	85,013	4,408	33,634	24,977	21,994	-14,342
Net Income	291,535	43,521	100,379	79,213	68,422	74,896
Net Income Growth	474%	-42%	-202.99%	121%	82%	-325%
Shares Outstanding (Diluted)	1,791.48	1,791.48	1,791.31	1,791.2	1,795.38	1,818.02
Shares Change (YoY)	-1%	-1%	0%	0%	0%	1%
EPS (Diluted)	162.73	24.29	56.03	44.22	38.11	41.19
EPS Growth	483%	-41%	-202.99%	121%	82%	-322%
Free Cash Flow	475,543	184,536	57,375	194,583	39,049	89,198
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	80.9%	82.58%	79.97%	79.87%	81.25%	83.26%
Operating Margin	17.76%	9.02%	23.55%	19.91%	18.29%	13.73%
Profit Margin	13.62%	8.09%	17.57%	15.1%	13.52%	16.3%
Free Cash Flow Margin	22.22%	34.3%	10.04%	37.11%	7.72%	19.42%
EBITDA	574,653	98,928	183,678	151,702	140,345	110,785
EBITDA Margin	26.86%	18.39%	32.15%	28.93%	27.74%	24.12%
D&A For EBITDA	194,594	50,360	49,136	47,294	47,804	47,683
EBIT	380,059	48,568	134,542	104,408	92,541	63,102
EBIT Margin	17.76%	9.02%	23.55%	19.91%	18.29%	13.73%
Effective Tax Rate	22.57%	9.17%	25.1%	23.97%	24.32%	-23.68%

Breakdown

TTM

03/31/2026

12/31/2025

09/30/2025

06/30/2025

03/31/2025

Revenue

2,139,245

537,925

571,206

524,320

505,794

459,294

Revenue Growth (YoY)

12%

17%

10%

13%

11%

Cost of Revenue

408,426

93,667

114,400

105,530

94,829

76,858

Gross Profit

1,730,819

444,258

456,806

418,790

410,965

382,436

Selling, General & Admin

860,312

234,699

221,779

206,837

196,997

211,316

Research & Development

314,827

95,943

75,595

71,591

71,698

76,229

Operating Expenses

1,350,760

395,690

322,264

314,382

318,424

319,334

Other Non Operating Income (Expenses)

Pretax Income

376,587

48,024

133,957

104,189

90,417

60,554

Income Tax Expense

85,013

4,408

33,634

24,977

21,994

-14,342

Net Income

291,535

43,521

100,379

79,213

68,422

74,896

Net Income Growth

474%

-42%

-202.99%

121%

82%

-325%

Shares Outstanding (Diluted)

1,791.48

1,791.31

1,791.2

1,795.38

1,818.02

Shares Change (YoY)

-1%

EPS (Diluted)

162.73

24.29

56.03

44.22

38.11

41.19

EPS Growth

483%

-41%

-202.99%

121%

82%

-322%

Free Cash Flow

475,543

184,536

57,375

194,583

39,049

89,198

Free Cash Flow Per Share

Gross Margin

80.9%

82.58%

79.97%

79.87%

81.25%

83.26%

Operating Margin

17.76%

9.02%

23.55%

19.91%

18.29%

13.73%

Profit Margin

13.62%

8.09%

17.57%

15.1%

13.52%

16.3%

Free Cash Flow Margin

22.22%

34.3%

10.04%

37.11%

7.72%

19.42%

EBITDA

574,653

98,928

183,678

151,702

140,345

110,785

EBITDA Margin

26.86%

18.39%

32.15%

28.93%

27.74%

24.12%

D&A For EBITDA

194,594

50,360

49,136

47,294

47,804

47,683

EBIT

380,059

48,568

134,542

104,408

92,541

63,102

EBIT Margin

17.76%

9.02%

23.55%

19.91%

18.29%

13.73%

Effective Tax Rate

22.57%

9.17%

25.1%

23.97%

24.32%

-23.68%

Follow-Up Questions

What are Astellas Pharma Inc.'s key financial statements?



According to the latest financial statement (Form-10K), Astellas Pharma Inc. has a total asset of $0, Net loss of $0

What are the key financial ratios for ALPMY?



Astellas Pharma Inc.'s Current ratio is 0, has a Net margin is 0, sales per share of $0.

How is Astellas Pharma Inc.'s revenue broken down by segment or geography?



Astellas Pharma Inc. largest revenue segment is Pharmaceutical, at a revenue of 1,912,323,000,000 in the most earnings release.For geography, United States is the primary market for Astellas Pharma Inc., at a revenue of 866,378,000,000.

Is Astellas Pharma Inc. profitable?



no, according to the latest financial statements, Astellas Pharma Inc. has a net loss of $0

Does Astellas Pharma Inc. have any liabilities?



no, Astellas Pharma Inc. has liability of 0

How many outstanding shares for Astellas Pharma Inc.?



Astellas Pharma Inc. has a total outstanding shares of 0

Astellas Pharma Inc. (ALPMY) Financial

ALPMY Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is Astellas Pharma, Inc.?

Astellas Pharma Inc. (ALPMY) Financial

ALPMY Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is Astellas Pharma, Inc.?

ALPMY Income

Follow-Up Questions

What are Astellas Pharma Inc.'s key financial statements?

What are the key financial ratios for ALPMY?

How is Astellas Pharma Inc.'s revenue broken down by segment or geography?

Is Astellas Pharma Inc. profitable?

Does Astellas Pharma Inc. have any liabilities?

How many outstanding shares for Astellas Pharma Inc.?